Abstract:OBJECTIVE To investigate the clinical significance of serum pepsinogen (PG) and Helicobacter pylori (Hp) IgG in the screening of gastric cancer and its precancerous diseases. METHODS A total of 158 patients with gastropathy who underwent routine examination during the period from May 2013 to February 2016 were collected and analyzed retrospectively. First, the patients were divided into four groups: 34 cases 15 patients with gastric cancer, 35 patients with chronic atrophic gastritis, 39 patients with gastric ulcer, and 50 patients with normal physical examination were selected as the control group. Pepsinogen I and pepsinogen II were detected by enzyme-linked immunosorbent assay (ELISA), and the ratio of PGI / PGⅡ was recorded as PGR. The detection of Hp-IgG antibody was obtained by colloidal gold method.Results: Compared with the control group, the levels of serum pepsinogen I and pepsinogen Ⅱ were significantly higher in patients with gastric ulcer and significantly lower in PGR (P＜0.05). The serum PG Ⅰ of gastric cancer and atrophic gastritis group was significantly lower (P＜0.05). There were no significant differences in the three indexes of the patients with superficial gastritis (P＜0.05). The positive rate of Hp infection was significantly higher than that of the control group (P＜0.05) , but there was no significant difference between the two groups (P＜0.05). Conclusion: The early diagnosis of gastric cancer and precancerous lesions ca be diagnosed by observing and observing the abnormal changes of PG level in the serum of patients, and there is no significant correlation between serum PG level and Hp infection. According to the clinical data, it can be seen that when the data are in PGⅠ≤70～80ng / ml, and PGR≤7.0～7.5 screening accuracy is high, can be used as a reference standard； clinical work should be detected serum pepsinogen level, gastroscopy, Pathology analysis of the three closely integrated, thereby improving the early diagnosis of cancer.